Log-in / Create Account  
 
DIA 2013 49th Annual Meeting
Click here to go to the previous page
Orphan Drug Development Strategy by Big and Medium/Small Pharmaceutical Industries
Track : Track 02: Project/Portfolio Management and Strategic Planning
Program Code: 402
Date: Thursday, June 27, 2013
Time: 9:00 AM to 10:30 AM  EST
Location: 104C
CHAIR :
 Noriaki Murao, MS (SCHNON), Representative, NM Consulting, Japan
SPEAKER (S):
 Kenneth Hitchner, MA (SPKNON), Vice President, Development Sciences Project Management, BioMarin Pharmaceutical Inc., United States
 Yoshihiko Ono, RPh (SPKNON), Executive Director, Head of Regulatory Affairs, Japan Development, MSD K.K., Japan
Michael Diem, MD (SPKNON), Director and Head of Business Development, GSK Rare Diseases, GlaxoSmithKline, United States
Description
This session will address considerations for planning the development and commercialization strategy of orphan drugs by large as well as small companies.

Session Recording
(Code: 402)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON5 Comp Access: Thursday Online Access Package - June 27, 2013
Handout Online
(Code: 402)
DIA 2013 Attendee:
Attendees Login
  
This session is a part of:
DIA 2013 Live Learning Center
CON5 Comp Access: Thursday Online Access Package - June 27, 2013
Orphan Drug Development Strategy by Big and Medium/Small Pharmaceutical Industries